Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase 2 Study of Lenvatinib or Regorafenib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Who Progressed After First-Line Immunotherapy-Based Combination Therapy (REVIVE)

NCT07495579 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT07495579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07495579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase 2 Study of Lenvatinib or Regorafenib in Patients With Unresectable or Metastatic Hepatocellular Carcinoma Who Progressed After First-Line Immunotherapy-Based Combination Therapy (REVIVE)
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
December 31, 2028
Enrollment
146 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)